Castleman disease presenting as lymphadenopathy in a female with systemic lupus erythematosus: A rare case report.
Castleman disease
lymphadenopathy
systemic lupus erythematosus
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
17
05
2023
revised:
19
08
2023
accepted:
04
09
2023
medline:
21
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
epublish
Résumé
Castleman disease is an infrequent disease that affects the lymph nodes and related tissues. The condition may manifest with lymphadenopathy, characterized by the enlargement of the lymph nodes, alongside additional symptoms such as high fever, nocturnal sweating, exhaustion, and loss of body mass. The diagnosis of Castleman disease typically entails a multifaceted approach that includes a physical examination, imaging modalities, and a biopsy of the lymph nodes that are affected. The selection of treatment modalities is contingent upon the classification and extent of the disease. Systemic lupus erythematosus (SLE) has been identified as a potential risk factor for the development of lymphoma, a condition that may manifest with lymphadenopathy resembling Castleman disease. Hence, it is crucial for individuals diagnosed with SLE and exhibiting lymphadenopathy to undergo a comprehensive assessment to exclude the possibility of any other associated disease. Although lymphadenopathy is a common symptom shared by both Castleman illness and SLE, these diseases have distinct etiologies and are treated in different ways. Seeking advice from a healthcare practitioner is crucial in order to obtain an accurate diagnosis and effective treatment. A 39-year-old female patient with a history of SLE since 18 years ago and lupus nephritis since 6 years ago which treated with Mycophenolic Acid 2 g daily, Hydroxychloroquine 400 mg daily, and low doses of Prednisolone. Also, Mycophenolic Acid has discontinued for her 5 months ago due to the reduction of proteinuria and the control of the disease. Although the association of Castleman Disease with SLE is infrequent, establishing a connection between them could prove advantageous in the treatment and etiology of diseases.
Identifiants
pubmed: 37731971
doi: 10.1002/ccr3.7922
pii: CCR37922
pmc: PMC10507217
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e7922Informations de copyright
© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Rheumatol Int. 2012 Jul;32(7):2189-93
pubmed: 20354856
Pathol Res Pract. 1997;193(8):565-71
pubmed: 9406250
BMJ Case Rep. 2014 Feb 27;2014:
pubmed: 24577173
Cancer. 1985 Nov 15;56(10):2446-51
pubmed: 2412685
Chin Med J (Engl). 2015 Sep 20;128(18):2551-2
pubmed: 26365980
N Engl J Med. 1954 Jun 10;250(23):1001-5
pubmed: 13165944
Am J Clin Pathol. 2020 Jul 7;154(2):215-224
pubmed: 32367142
Rheumatol Int. 2021 Feb;41(2):475-479
pubmed: 32797278
Acta Clin Belg. 2004 May-Jun;59(3):161-4
pubmed: 15462513
Haematologica. 2004 Apr;89(4):ECR03
pubmed: 15075095
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
Cancer. 1972 Mar;29(3):670-83
pubmed: 4551306
Blood Adv. 2020 Dec 8;4(23):6039-6050
pubmed: 33284946
Pathol Int. 2000 Apr;50(4):304-12
pubmed: 10849316